ValuEngine Downgrades HUTCHISON CHINA/S (NASDAQ:HCM) to Hold
HCM has been the topic of several other research reports. Cantor Fitzgerald assumed coverage on shares of HUTCHISON CHINA/S in a report on Thursday, March 12th. They issued an “overweight” rating on the stock. BidaskClub raised shares of HUTCHISON CHINA/S from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 25th. Finally, Zacks Investment Research downgraded shares of HUTCHISON CHINA/S from a “hold” rating to a “sell” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $26.50.
NASDAQ HCM opened at $28.53 on Thursday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.66 and a current ratio of 2.80. The firm has a market cap of $3.81 billion, a PE ratio of -35.66 and a beta of 1.15. HUTCHISON CHINA/S has a one year low of $14.74 and a one year high of $29.92. The firm’s fifty day moving average is $23.18 and its two-hundred day moving average is $23.15.
About HUTCHISON CHINA/S
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.